Aoxing Pharmaceutical (AXN +7.4%) pops after the drug-maker reported a $15.9M net loss for FY12, but total revenue rose 22% year over year to $8.13M. The revenue gain was largely due to a 33% increase in sales of the company's main product, Zhongtongan, which is now being marketed for gynecological and orthopedic applications, in addition to its core dental market. Overall, Zhongtongan accounted for 89% of the company's FY12 sales.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs